| Hazard Information | Back Directory | [Uses]
Mavrilimumab (CAM-3001) is an investigational human IgG4 monoclonal antibody (MAb) targeting GM-CSF receptor alpha which is currently being developed for the treatment of RA. GM-CSF plays a central role in the pathogenesis of rheumatoid arthritis (RA) through the activation, differentiation, and survival of macrophages and neutrophils. | [in vivo]
Mavrilimumab (3-100 mg/kg, iv, once a week for at least 11 weeks) 可抑制 GM-CSF 信号转导，长期大剂量给药可导致肺泡巨噬细胞中中性脂质沉积、泡沫细胞形成、胆固醇裂隙以及肉芽肿性炎症。Mavrilimumab 在食蟹猴中具有免疫原性，多次给药后可产生抗药抗体，从而加速药物清除并降低暴露量[2]。 | Animal Model: | Cynomolgus monkey models[2] | | Dosage: | 3-100 mg/kg | | Administration: | iv, once a week for at least 11 weeks | | Result: | Produced foam cells in the lungs. |
|
|
| Company Name: |
Biolab Reagents
|
| Tel: |
18108604356 18108604356 |
| Website: |
www.biolabreagent.com/ |
| Company Name: |
Cell Sciences
|
| Tel: |
9785721070 |
| Website: |
www.cellsciences.com |
|